About Vardhman Chemtech
Vardhman Chemtech is a Healthcare company based in Chandigarh (India) founded in 1996 by Vivek Gupta and Suyog Jain. Manufacturer of bulk drugs, intermediates and fine chemicals. Vardhman Chemtech has raised $14 million across 1 funding round from investors including Piramal Group. The company has 98 employees. Its Indian entity Vardhman Chemtech Limited reported revenue of ₹209 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.
Company details
Vardhman Chemtech is an integrated manufacturer of bulk drugs, intermediates and fine chemicals in the Isoxazoles segment of penicillin. Currently, the company manufactures APIs and their variants, which it supplies to Indian drug-makers. The company also exports to key markets, such as the Far East, Indian sub-continent, SAARC countries, China, the Middle East, North Africa, East Africa, West Africa, Latin America and the Russian bloc. Their API facility is US FDA certified.
- Headquarters Chandigarh, India
- Employees 98
- Founders Vivek Gupta, Suyog Jain
- SectorsHealthcare
- Website vardhmanchemtech.com
- Social LinkedIn
- Legal Name Vardhman Chemtech Limited
- Date of Incorporation 21 Aug, 1996
- Jurisdiction Chandigarh, India
- Annual Revenue₹209 Cr
FY 2025 · -13% YoY
- Net Profit₹3.61 Cr
FY 2025 · 2% margin
- EBITDA₹21.78 Cr
FY 2025 · 10% margin
- Total Equity Funding$14M (USD)
in 1 rounds
- Latest Funding Round$14M (USD), Private Equity Round
Mar 2012
- Investors
- Employee Count98
Associated legal entities of Vardhman Chemtech
Vardhman Chemtech is associated with 2 registered companies on The Company Check; the primary company is Vardhman Chemtech Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vardhman Chemtech Limited CIN U24117CH1996PLC018656 | Active | 21 Aug 1996 | Chandigarh, Chandigarh | ₹209 Cr | 181 | 4 | View details |
| Dpb Antibiotics Private Limited CIN U51397CH2010PTC046352 | Active | 27 Mar 2010 | Chandigarh, Chandigarh | ₹0.0 Cr | 4 | View details |
Funding Insights of Vardhman Chemtech
Vardhman Chemtech has successfully raised a total of $14M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $14 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14M
- Total Rounds 1
- Last Round Private Equity Round — $14M
- First Round $14M
(Mar 2012)
- Investors Count 1
All 1 funding rounds of Vardhman Chemtech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2012 | $14M | Private Equity Round | – | – |
1 investors in total: 1 institutional.
Investors in Vardhman Chemtech
Vardhman Chemtech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Piramal Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | 1984 | piramal.com | Mumbai, India |
Investor details for Vardhman Chemtech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Vardhman Chemtech Limited (Vardhman Chemtech)
Vardhman Chemtech Limited is the primary company behind Vardhman Chemtech. The boards of the 2 registered companies of Vardhman Chemtech currently have 4 directors; the longest-serving is Devang Manharlal Ajmera, appointed in 2021. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Devang Manharlal Ajmera DIN 02366861 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Antibiotics Private Limited |
| Piyush Manharlal Ajmera DIN 02366873 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Antibiotics Private Limited |
| Bhavin Manharlal Ajmera DIN 02366882 | Director | 02 Feb 2021 | 5 yrs 8 mo | Vardhman Chemtech Limited, Dpb Antibiotics Private Limited |
| Sharvan Bhatt DIN 07674478 | Whole-time director | 21 Jul 2021 | 5 yrs 3 mo | Vardhman Chemtech Limited, Dpb Antibiotics Private Limited |
People of Vardhman Chemtech
2 people are tracked at Vardhman Chemtech (2 in leadership); the tracked headcount is 98.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Founder | Leadership |
Complete people profiles for Vardhman Chemtech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Vardhman Chemtech
Figures of Vardhman Chemtech Limited, the primary company behind Vardhman Chemtech, for FY 2025. Revenue was ₹209 Cr (-13% year on year). Net profit was ₹3.61 Cr (2% margin). EBITDA was ₹21.78 Cr (10% margin). Revenue has grown at a compounded annual rate of -4% over three years and +93% over five years.
- ₹209 CrRevenue · FY 2025 · -13% YoY
- ₹3.61 CrNet profit · 2% margin
- ₹21.78 CrEBITDA · 10% margin
- ₹10 LakhPaid-up capital
- 181Employees (provident fund records)
- -4%Revenue CAGR, 3 years
- +93%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Vardhman Chemtech Limited are on its company page.
Detailed financial statements for Vardhman Chemtech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vardhman Chemtech
2 dated milestones of Vardhman Chemtech across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Vardhman Chemtech is founded.
- Funding First funding round of $14.0M.
Competitors of Vardhman Chemtech
Vardhman Chemtech has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed competitors of Vardhman Chemtech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Vardhman Chemtech (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vardhman Chemtech
Complete news archive for Vardhman Chemtech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vardhman Chemtech
Vardhman Chemtech was founded in 1996 and raised its 1st funding round 16 years after it was founded.
Vardhman Chemtech is headquartered in Chandigarh, India.
Vardhman Chemtech is a funded company, having raised a total of $14M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $14M, raised on Mar 2012.
Vardhman Chemtech has 98 employees.
The primary company behind Vardhman Chemtech, Vardhman Chemtech Limited, reported revenue of ₹209 Cr for FY 2025, down 13% year on year.
Vardhman Chemtech is an integrated manufacturer of bulk drugs, intermediates and fine chemicals in the Isoxazoles segment of penicillin. Currently, the company manufactures APIs and their variants, which it supplies to Indian drug-makers. The company also exports to key markets, such as the Far East, Indian sub-continent, SAARC countries, China, the Middle East, North Africa, East Africa, West Africa, Latin America and the Russian bloc. Their API facility is US FDA certified.
Vardhman Chemtech's top competitors include Laurus Labs, Symbiotec and SeQuent.
Vardhman Chemtech has 1 investor. Key investors include Piramal Group.
Vardhman Chemtech is associated with 2 legal entities: Vardhman Chemtech Limited, Dpb Antibiotics Private Limited.
The legal entities of Vardhman Chemtech currently have 4 directors, including Devang Manharlal Ajmera, Piyush Manharlal Ajmera, Bhavin Manharlal Ajmera and others.